Vanessa Gonzalez-Covarrubias

Prof. Vanessa Gonzalez-Covarrubias

INMEGEN
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
VGVanessa Gonzalez-Covarrubias
Vanessa Gonzalez-Covarrubias
EMEduardo Martinez-Martinez
Eduardo Martinez-Martinez
LBLaura Del Bosque-Plata
Laura Del Bosque-Plata
The metabolome offers a dynamic, comprehensive, and precise picture of the phenotype. Current high-throughput technologies have allowed the discovery of relevant metabolites that characterize a wide variety of human phenotypes with respect to health, disease, drug monitoring, and even aging. Metabolomics, parallel to genomics, has led to the discovery of biomarkers and has aided in the understanding of a diversity of molecular mechanisms, highlighting its application in precision medicine. This review focuses on the metabolomics that can be applied to improve human health, as well as its trends and impacts in metabolic and neurodegenerative diseases, cancer, longevity, the exposome, liquid biopsy development, and pharmacometabolomics. The identification of distinct metabolomic profiles will help in the discovery and improvement of clinical strategies to treat human disease. In the years to come, metabolomics will become a tool routinely applied to diagnose and monitor health and disease, aging, or drug development. Biomedical applications of metabolomics can already be foreseen to monitor the progression of metabolic diseases, such as obesity and diabetes, using branched-chain amino acids, acylcarnitines, certain phospholipids, and genomics; these can assess disease severity and predict a potential treatment. Future endeavors should focus on determining the applicability and clinical utility of metabolomic-derived markers and their appropriate implementation in large-scale clinical settings.

29 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
CCCarlos D Cruz-Hernandez
Carlos D Cruz-Hernandez
GRGriselda Rodríguez-Martinez
Griselda Rodríguez-Martinez
SRSergio A Cortes Ramirez
Sergio A Cortes Ramirez
MMMiguel Morales
Miguel Morales
JBJenie Marian Cruz Burgos
Jenie Marian Cruz Burgos
MRMAURICIO RODRIGUEZ-DORANTES
MAURICIO RODRIGUEZ-DORANTES
Despite of the capacity that several drugs have for specific inhibition of the androgen receptor (AR), in most cases, PCa progresses to an androgen-independent stage. In this context, the development of new targeted therapies for prostate cancer (PCa) has remained as a challenge. To overcome this issue, new tools, based on nucleic acids technology, have been developed. Aptamers are small oligonucleotides with a three-dimensional structure capable of interacting with practically any desired target, even large targets such as mammalian cells or viruses. Recently, aptamers have been studied for treatment and detection of many diseases including cancer. In PCa, numerous works have reported their use in the development of new approaches in diagnostics and treatment strategies. Aptamers have been joined with drugs or other specific molecules such as silencing RNAs (aptamer–siRNA chimeras) to specifically reduce the expression of oncogenes in PCa cells. Even though these studies have shown good results in the early stages, more research is still needed to demonstrate the clinical value of aptamers in PCa. The aim of this review was to compile the existing scientific literature regarding the use of aptamers in PCa in both diagnosis and treatment studies. Since Prostate-Specific Membrane Antigen (PSMA) aptamers are the most studied type of aptamers in this field, special emphasis was given to these aptamers.

10 October 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
VGVanessa Gonzalez-Covarrubias
Vanessa Gonzalez-Covarrubias
MMMarlet Morales-Franco
Marlet Morales-Franco
OCOmar F. Cruz-Correa
Omar F. Cruz-Correa
AMAngélica Martínez-Hernández
Angélica Martínez-Hernández
HGHumberto Garcia-Ortiz
Humberto Garcia-Ortiz
XSXavier Soberón
Xavier Soberón
The identification and characterization of pharmacogenetic variants in Latin American populations is still an ongoing endeavor. Here, we investigated SNVs on genes listed by the Pharmacogenomics Knowledge Base in 1284 Mestizos and 94 Natives from Mexico. Five institutional cohorts with NGS data were retrieved from different research projects at INMEGEN, sequencing files were filtered for 55 pharmacogenes present in all cohorts to identify novel and known variation. Bioinformatic tools VEP, PROVEAN, and FATHMM were used to assess, in silico, the functional impact of this variation. Next, we focused on 17 genes with actionable variants that have been clinically implemented. Allele frequencies were compared with major continental groups and differences discussed in the scope of a pharmacogenomic impact. We observed a wide genetic variability for known and novel SNVs, the largest variation was on UGT1A > ACE > COMT > ABCB1 and the lowest on APOE and NAT2. Although with allele frequencies around 1%, novel variation was observed in 16 of 17 PGKB genes. In Natives we identified 59 variants and 58 in Mestizos. Several genes did not show novel variation, on CYP2B6, CYP2D6, and CYP3A4 in Natives; and APOE, UGT1A, and VKORC1 in Mestizos. Similarities in allele frequency, comparing major continental groups for VIP pharmacogenes, hint towards a comparable PGx for drugs metabolized by UGT1A1, DPYD, ABCB1, CBR3, COMT, and TPMT; in contrast to variants on CYP3A5 and CYP2B6 for which significant MAF differences were identified. Our observations offer some discernment into the extent of pharmacogenetic variation registered up-to-date in Mexicans and contribute to quantitatively dissect actionable pharmacogenetic variants in Natives and Mestizos.

17 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JBJenie Marian Cruz Burgos
Jenie Marian Cruz Burgos
SRSergio A Cortes Ramirez
Sergio A Cortes Ramirez
ALAlberto Losada
Alberto Losada
MMMiguel Morales
Miguel Morales
EMEduardo Martinez-Martinez
Eduardo Martinez-Martinez
MRMAURICIO RODRIGUEZ-DORANTES
MAURICIO RODRIGUEZ-DORANTES
Metastasis remains the leading cause of mortality in prostate cancer patients. The presence of tumor cells in lymph nodes is an established prognostic indicator for several cancer types, such as melanoma, breast, oral, pancreatic, and cervical cancers. Emerging evidence highlights the role of microRNAs enclosed within extracellular vesicles as facilitators of molecular communication between tumors and metastatic sites in the lymph nodes. This study aims to investigate the potential diagnostic utility of EV-derived microRNAs in liquid biopsies for prostate cancer. By employing microarrays on paraffin-embedded samples, we characterized the microRNA expression profiles in metastatic lymph nodes, non-metastatic lymph nodes, and primary tumor tissues of prostate cancer. Differential expression of microRNAs was observed in metastatic lymph nodes compared to prostate tumors and non-metastatic lymph node tissues. Three microRNAs (miR-140-3p, miR-150-5p, and miR-23b-3p) were identified as differentially expressed between tissue and plasma samples. Furthermore, we evaluated the expression of these microRNAs in exosomes derived from prostate cancer cells and plasma samples. Intriguingly, high Gleason score samples exhibited the lowest expression of miR-150-5p compared to control samples. Pathway analysis suggested a potential regulatory role for miR-150-5p in the Wnt pathway and bone metastasis. Our findings suggest EV-derived miR-150-5p as a promising diagnostic marker for identifying patients with high-grade Gleason scores and detecting metastasis at an early stage.

2 January 2015 in Gene
Verified
Journal Article
Closed access
BVBeatriz Villegas-Torres
Beatriz Villegas-Torres
FSFrancisco Sánchez-Girón
Francisco Sánchez-Girón
KJKarla Jaramillo-Villafuerte
Karla Jaramillo-Villafuerte
XSXavier Soberón
Xavier Soberón
VGVanessa Gonzalez-Covarrubias
Vanessa Gonzalez-Covarrubias

7 July 2016 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
VGVanessa Gonzalez-Covarrubias
Vanessa Gonzalez-Covarrubias
José Jaime Martínez-MagañaJosé Jaime Martínez-Magaña
José Jaime Martínez-Magaña
RCRegina Coronado-Sosa
Regina Coronado-Sosa
BVBeatriz Villegas-Torres
Beatriz Villegas-Torres
AGAlma D. Genis-Mendoza
Alma D. Genis-Mendoza
XSXavier Soberón
Xavier Soberón